Ispaghula Husk
Brand names: Fybogel, Metamucil, Regulan
Ispaghula husk (psyllium) is a bulk-forming laxative used in the management of constipation and to maintain regular bowel function, including in conditions where a softer, bulkier stool is helpful.
Adult dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to ispaghula husk or to any of the excipients
- Patients with a sudden change in bowel habit that has persisted more than two weeks
- Undiagnosed rectal bleeding, and failure to defecate following the use of a laxative
- Abnormal constrictions in the gastro-intestinal tract, diseases of the oesophagus and cardia, intestinal obstruction, faecal impaction, natural or drug-induced reduction of gut motility, and colonic atony such as senile mega-colon
- Patients who have difficulty in swallowing or any throat problems
Side effects
- Hypersensitivity disorders (frequency not known), including rash, anaphylaxis, pruritus and bronchospasm
- Flatulence and abdominal distension (frequency not known) — a small amount may occur during the first few days of treatment but should diminish with continued treatment
- Intestinal obstruction, oesophageal obstruction and faecal impaction (frequency not known), particularly if swallowed with insufficient fluid; symptoms can be chest pain, vomiting, or difficulty in swallowing or breathing
- Conjunctivitis and rhinitis (frequency not known), reflecting the allergenic potential of ispaghula/psyllium husk
- Skin rash (frequency not known)
Interactions
- Should not be used together with medicinal products known to inhibit peristaltic movement (e.g. opioids), in order to decrease the risk of gastrointestinal obstruction — and then only under medical supervision (from §4.4)
- Enteral absorption of concomitantly administered medicines may be affected — the SPC directs that the product be taken at least half an hour to 1 hour before or after other medicines. NOTE: §4.5 itself is cut off mid-sentence ('Enteral absorption of …') in this bundle, so the full UK interaction list has not been retrieved — clinician to source it
Clinical monograph
How it works
Its soluble fibre absorbs water in the gut to increase faecal mass, which stimulates peristalsis and softens the stool.
Prescribing in practice
- Take with plenty of fluid and avoid taking immediately before going to bed, as inadequate fluid intake risks intestinal or oesophageal obstruction and impaction.
- It is contraindicated in intestinal obstruction, faecal impaction and conditions such as colonic atony where bulking agents are inappropriate.
- Full effect develops gradually over days, so it is not suitable for rapid relief of acute constipation.
Monitoring
Routine laboratory monitoring is not required; review the bowel response and ensure adequate fluid intake is maintained.
Counselling the patient
- Mix the dose with plenty of water and drink it straight away, and keep your fluid intake up during the day.
- Do not take it just before lying down or going to bed.
Evidence & guidelines
Bulk-forming laxatives such as ispaghula are recommended as a first-line option for constipation in line with NICE guidance.
Reference: NICE CG61 Irritable Bowel Syndrome; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021